Abstract: The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologus gene incorporated into an insertion-region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.

Abstract: The present invention is directed to purified polypeptides comprising the .gamma. T cell antigen receptor (TCR) polypeptide, the .delta. TCR polypeptide, a .gamma., .delta. TCR complex, or a fragment thereof containing an epitope. The invention also relates to nucleic acid sequences encoding such polypeptides, and subsequences thereof. In specific embodiments, the invention relates to nucleic acid sequences comprising variable, diversity, joining, or constant regions of the .delta. TCR gene sequence. The invention also relates to monoclonal antibodies specifically reactive with an epitope of the gamma or delta TCR polypeptides. In specific embodiments, these antibodies are reactive with the delta constant region, the delta variable region, or gamma constant region. Such antibodies can be identified by detecting co-modulation of the CD3 antigen. In another embodiment, the invention relates to compositions comprising substantially purified cells which express both a .gamma., .delta. TCR and the CD4 antigen.

Abstract: This invention provides an isolated nucleic acid molecule encoding human myeloblastin, a nucleic acid probe for detecting myeloblastin, and an antisense oligodeoxynucleotide complementary to myeloblastin mRNA. The invention also provides antibodies directed to myeloblastin, and purified myeloblastin. The invention further provides a pharmaceutical composition to inhibit proliferation and induce differentiation of leukemia cells, a myeloblastin inhibitor, and a factor suppressing myeloblastin expression. The invention provides methods for identifying leukemia cells which express different quantities of myeloblastin, treating leukemia, and for preparing purified myeloblastin.

Abstract: The present invention relates to nucleic acid sequences encoding brain derived neurotrophic factor (BDNF), as well as BDNF protein produced in quantity using these nucleic acid sequences, as well as fragments and derivatives thereof. In addition, the invention relates to pharmacologic compositions and therapeutic uses of BDNF, having provided, for the first time, the ability to generate sufficient quantities of substantially pure BDNF for clinical use. The invention also relates to antibodies directed toward BDNF or fragments thereof, having provided a method for generating sufficient immunogen. Further, by permitting a comparison of the nucleic acid sequences of BDNF and NGF, the present invention provides for the identification of homologous regions of nucleic acid sequence between BDNF and NGF, thereby defining a BDNF/NGF gene family; the invention provides a method for identifying an disolating additional members of this gene family.

Abstract: A method of suppressing tumor formation in a vertebrate by administering JE/MCP-1 is described. Also described are methods of treating localized complications of malignancies and methods of combatting parasitic infection by administering JE/MCP-1.

Abstract: Purified protein known as platelet TGF-.beta.1-BP (transforming growth factor-.beta.1-binding protein) is described. The protein is useful for purposes such as the production of antisera which are useful in identifying complexes containing the binding protein, as well as in formation of labeled probes. Also described are purified DNA which expresses the protein, as well as messenger RNA translated into the protein. The protein contains 16 epidermal growth factors (EGF) like repeats, and 3 repeats not found in other proteins. The DNA for the protein is found to contain consensus sequences for hydroxylation of asparagine/aspartic acid residues, and, in the purified protein beta hydroxylated asparagine residues were found.

Abstract: The glycoprotein known as P40, characterized by a molecular weight of from about 30 to 40 kilodaltons and an isoelectric point of about 10, previously recognized as a helper T cell growth factor, also enhances growth and proliferation of mast cells and their maintenance viability and differentation status in vitro.

Abstract: Hollow fiber structures for culturing mammalian cells in an agitated media are disclosed. These hollow fibers have a cylindrical wall surrounding a lumen preferably open at opposite ends of the fiber and have a length along the axis parallel to the lumen of not more than 5 centimeters. Hollow fiber structures which have their exterior surface coated to prevent cell attachment and growth thereon are also disclosed.

Abstract: This invention is in the field of cell and/or tissue culture. In particular, this invention relates to methods which adapt cells to a desired phenotype by exposing the cells to high levels of ammonia in culture, and subsequently transferring the adapted cells to a new culture medium in which there is no initial level of ammonia or the initial level of ammonia is below the level to which cells have been exposed to during the adaptation process. In this new culture medium, the adapted cells express the desired phenotype of growing to a higher viable cell density, and/or remaining viable for a longer period of time, and/or producing more of a desired cell product than their non-adapted counterparts grown in the same medium. This invention includes the adapted cells produced thereby and their cell products.

Abstract: A process is provided for isolating and purifying biologically active RNA from a biological sources containing RNA, DNA and other cellular materials. The process involves contacting the RNA-containing source with particles comprising siliceous material, such as finely-divided glass, in the presence of a binding solution comprising concentrated, acidified chaotropic salt. Under these conditions, RNA, but not DNA, binds selectively to the siliceous material, and can be separated easily from the other components of the sample. Preferably, the selective binding process is applied to biological cells containing RNA of interest. Intact cells are disrupted by exposing them to a lysing solution comprising, as its main component, concentrated, acidified chaotropic salt. The RNA is then isolated and purified from the lysate using the selective binding process of the invention.

Abstract: Pharmaceutical compositions and dressings useful in wound healing are provided. The pharmaceutical compositions comprise thrombospondin as the active ingredient.

Abstract: A method for synthesizing sulfurized oligonucleotide analogs, such as phosphorothioate and phosphorodithioate analogs, is provided that employs a thiophosphorus compound, such as a thiophosphoric, dithiophosphoric, thiophosphinic, or dithiophosphinic acid disulfide or polysulfide, as a sulfurizing agent. The method of the invention may be used to sulfurize any phosphorous(III)-containing intermediate. Preferably, the method is practiced on a commercial DNA synthesizer using phosphoramidite and/or phosphorthioamidite intermediates.

Abstract: The invention relates to a container for fertilization of human ovocytes in the absence of CO.sub.2 which may be done in an incubator at 37.degree. C. or in the vaginal cavity. The container will be held in the posterior fornix of the vaginal cavity by a flexible ring comprised of a metal strip 17 sheathed in rubber 18 to which is fixed a rubber pouch 19 in which the container is placed. This device thus permits inter-vaginal fertilization of human ovocytes in the absence of CI.sub.2 -enriched air, the vaginal cavity replacing the incubator conventionally used.

Abstract: A novel bacterial proteinaceous immunoglobulin G receptor is disclosed. The proteinaceous factor binds all four subclasses of human IgG, as well as rabbit, swine, equine, bovine, sheep, and goat IgG. The proteinaceous factor is obtained from biologically pure cultures of Gardnerella vaginalis such as those having the identifying characteristics of ATCC Deposit No. 55195.

Abstract: The disclosure describes novel immunosuppressive agents isolated from syncytiotrophoblast microvilli membranes by preparing a minutely subdivided and solubilized preparation of said membranes and isolating the unreduced N-linked oligosaccharides from an extract of the preparation.